Literature DB >> 27068265

High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina.

G Moya1,2,3, P Dorado1, V Ferreiro3, M E G Naranjo1, E M Peñas-Lledó1, A LLerena1,4.   

Abstract

A twofold higher frequency of CYP2D6 ultrarapid metabolizers (estimated from genotype: gUMs) was reported among Ashkenazi Jews (AJ) living in New York (USA) than in other North American Caucasians, which might be important to guide the prescription for CYP2D6 substrates in AJ communities around the world. This study was aimed to determine whether the high frequency of CYP2D6 gUMs described in AJ from USA was replicated in AJ from Argentina when compared with other multiethnic admixture Argentines (GA). The frequency of the most common allelic variants and of CYP2D6 gUMs (>2 active genes) and poor metabolizers (0 active genes, gPMs) was also compared among the studied Argentine populations. CYP2D6 genotyping was performed in 173 AJ and 246 GA DNA samples of unrelated donors from the metropolitan area of Buenos Aires. CYP2D6 alleles (*2, *3, *4, *5, *6, *10, *17, *35, *41 and multiple copies), genotypes and functional phenotype frequencies were determined. The frequencies of gUMs and gPMs in AJ from Argentina were 11.5% and 5.2%, respectively, whereas in GA, the frequencies of gUM and gPMs were 6.5% and 4.9%, respectively. Comparisons between AJ and GA showed that gUMs frequencies were twofold higher (P<0.05) in AJ than GA. CYP2D6*35 allele was more frequent in GA than AJ, whereas CYP2D6*41 and *1xN were more frequent in AJ than in GA (P<0.05). This study supports the previously reported high frequency of gUMs on another Ashkenazi population in New York. The present findings also support the interethnic variability of CYP2D6 genetic polymorphism in the overall Argentine population.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27068265     DOI: 10.1038/tpj.2016.27

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  30 in total

1.  CYP2D6 and the severity of suicide attempts.

Authors:  Eva M Peñas-Lledó; Hilario Blasco-Fontecilla; Pedro Dorado; Concepción Vaquero-Lorenzo; Enrique Baca-García; Adrián Llerena
Journal:  Pharmacogenomics       Date:  2011-12-05       Impact factor: 2.533

2.  Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations.

Authors:  Kenji Nakai; Wataru Habano; Keiko Nakai; Noriko Fukushima; Akira Suwabe; Shogo Moriya; Kaoru Osano; David Gurwitz
Journal:  Life Sci       Date:  2005-08-18       Impact factor: 5.037

3.  Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.

Authors:  S A Scott; S Martis; I Peter; Y Kasai; R Kornreich; R J Desnick
Journal:  Pharmacogenomics J       Date:  2011-03-01       Impact factor: 3.550

4.  High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders.

Authors:  E M Peñas-Lledó; P Dorado; Z Agüera; M Gratacós; X Estivill; F Fernández-Aranda; A Llerena
Journal:  Mol Psychiatry       Date:  2011-02-15       Impact factor: 15.992

Review 5.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.

Authors:  J K Hicks; J R Bishop; K Sangkuhl; D J Müller; Y Ji; S G Leckband; J S Leeder; R L Graham; D L Chiulli; A LLerena; T C Skaar; S A Scott; J C Stingl; T E Klein; K E Caudle; A Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2015-06-29       Impact factor: 6.875

6.  Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.

Authors:  Pedro Dorado; Macarena C Cáceres; Eulalia Pozo-Guisado; Ma-Li Wong; Julio Licinio; Adrian Llerena
Journal:  Biotechniques       Date:  2005-10       Impact factor: 1.993

7.  Codeine intoxication associated with ultrarapid CYP2D6 metabolism.

Authors:  Yvan Gasche; Youssef Daali; Marc Fathi; Alberto Chiappe; Silvia Cottini; Pierre Dayer; Jules Desmeules
Journal:  N Engl J Med       Date:  2004-12-30       Impact factor: 91.245

8.  Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

Authors:  Stuart A Scott; Lisa Edelmann; Ruth Kornreich; Robert J Desnick
Journal:  Am J Hum Genet       Date:  2008-01-17       Impact factor: 11.025

Review 9.  Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

Authors:  K R Crews; A Gaedigk; H M Dunnenberger; J S Leeder; T E Klein; K E Caudle; C E Haidar; D D Shen; J T Callaghan; S Sadhasivam; C A Prows; E D Kharasch; T C Skaar
Journal:  Clin Pharmacol Ther       Date:  2014-01-23       Impact factor: 6.875

10.  Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.

Authors:  S Martis; I Peter; J-S Hulot; R Kornreich; R J Desnick; S A Scott
Journal:  Pharmacogenomics J       Date:  2012-04-10       Impact factor: 3.550

View more
  1 in total

1.  High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.

Authors:  M E G Naranjo; F de Andrés; A Delgado; J Cobaleda; E M Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2016-06-07       Impact factor: 3.550

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.